Elo Mutual Pension Insurance Co Sells 303 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Elo Mutual Pension Insurance Co decreased its position in IQVIA Holdings Inc. (NYSE:IQV) by 1.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,357 shares of the medical research company’s stock after selling 303 shares during the period. Elo Mutual Pension Insurance Co’s holdings in IQVIA were worth $3,459,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Blair William & Co. IL boosted its stake in IQVIA by 8.8% in the 2nd quarter. Blair William & Co. IL now owns 4,072 shares of the medical research company’s stock worth $861,000 after purchasing an additional 328 shares in the last quarter. Vanguard Personalized Indexing Management LLC raised its position in IQVIA by 10.9% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 15,847 shares of the medical research company’s stock worth $3,347,000 after buying an additional 1,552 shares during the last quarter. Meiji Yasuda Asset Management Co Ltd. raised its position in IQVIA by 3.0% in the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 9,112 shares of the medical research company’s stock worth $1,927,000 after buying an additional 264 shares during the last quarter. Mercer Global Advisors Inc. ADV raised its position in IQVIA by 21.1% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 13,043 shares of the medical research company’s stock worth $2,746,000 after buying an additional 2,277 shares during the last quarter. Finally, Argent Trust Co raised its position in IQVIA by 7.3% in the 2nd quarter. Argent Trust Co now owns 19,490 shares of the medical research company’s stock worth $4,121,000 after buying an additional 1,327 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Up 1.1 %

Shares of IQV stock opened at $242.67 on Thursday. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85. IQVIA Holdings Inc. has a one year low of $167.42 and a one year high of $261.73. The company’s fifty day moving average price is $239.74 and its 200-day moving average price is $234.18. The company has a market capitalization of $44.21 billion, a price-to-earnings ratio of 33.15, a PEG ratio of 2.24 and a beta of 1.49.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. The business had revenue of $3.81 billion for the quarter, compared to analysts’ expectations of $3.79 billion. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The business’s quarterly revenue was up 2.3% on a year-over-year basis. During the same period last year, the firm earned $2.22 earnings per share. Sell-side analysts expect that IQVIA Holdings Inc. will post 10.25 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the transaction, the insider now owns 19,536 shares of the company’s stock, valued at $4,812,302.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 1.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. JPMorgan Chase & Co. boosted their target price on IQVIA from $260.00 to $288.00 and gave the stock an “overweight” rating in a research report on Monday, August 5th. Evercore ISI boosted their target price on IQVIA from $230.00 to $270.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 23rd. UBS Group boosted their target price on IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. Royal Bank of Canada initiated coverage on IQVIA in a research report on Wednesday, September 4th. They issued an “outperform” rating and a $275.00 target price for the company. Finally, Jefferies Financial Group lowered shares of IQVIA from a “buy” rating to a “hold” rating and reduced their price target for the company from $266.00 to $242.00 in a research report on Wednesday, July 24th. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and a consensus price target of $266.67.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.